Tandem Diabetes Care (NASDAQ:TNDM) Downgraded by StockNews.com to Sell

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday.

TNDM has been the subject of a number of other reports. Stifel Nicolaus upgraded shares of Tandem Diabetes Care from a "hold" rating to a "buy" rating and increased their price objective for the stock from $24.00 to $37.00 in a research note on Tuesday, March 26th. Citigroup raised their price target on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research note on Wednesday, April 3rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $37.00.

Tandem Diabetes Care Stock Down 2.0 %

Shares of TNDM traded down $0.70 on Thursday, hitting $33.87. The company's stock had a trading volume of 622,857 shares, compared to its average volume of 1,793,297. The firm's fifty day moving average price is $28.91 and its 200-day moving average price is $24.40. Tandem Diabetes Care has a fifty-two week low of $13.82 and a fifty-two week high of $43.09. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -9.85 and a beta of 1.12.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. On average, equities research analysts expect that Tandem Diabetes Care will post -1.62 EPS for the current year.

Institutional Trading of Tandem Diabetes Care

A number of hedge funds and other institutional investors have recently modified their holdings of TNDM. State of Wyoming grew its position in Tandem Diabetes Care by 45.8% during the 4th quarter. State of Wyoming now owns 821 shares of the medical device company's stock worth $37,000 after acquiring an additional 258 shares during the last quarter. RiverPark Advisors LLC bought a new stake in shares of Tandem Diabetes Care during the fourth quarter worth about $27,000. Signaturefd LLC increased its stake in shares of Tandem Diabetes Care by 871.8% in the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company's stock valued at $50,000 after buying an additional 1,517 shares during the period. Stephens Inc. AR raised its holdings in Tandem Diabetes Care by 17.6% in the 1st quarter. Stephens Inc. AR now owns 2,120 shares of the medical device company's stock valued at $86,000 after buying an additional 317 shares during the last quarter. Finally, Mackenzie Financial Corp acquired a new stake in Tandem Diabetes Care during the 1st quarter worth approximately $256,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.